keyword
MENU ▼
Read by QxMD icon Read
search

intermediate risk prostate cancer genomic

keyword
https://www.readbyqxmd.com/read/28528811/ability-of-a-genomic-classifier-to-predict-metastasis-and-prostate-cancer-specific-mortality-after-radiation-or-surgery-based-on-needle-biopsy-specimens
#1
Paul L Nguyen, Zaid Haddad, Ashley E Ross, Neil E Martin, Samineh Deheshi, Lucia L C Lam, Jijumon Chelliserry, Jeffrey J Tosoian, Tamara L Lotan, Daniel E Spratt, Radka S Stoyanova, Sanoj Punnen, Kaye Ong, Christine Buerki, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Kasra Yousefi, Voleak Choeurng, Elai Davicioni, Bruce J Trock, Christopher J Kane, Alan Pollack, John W Davis, Felix Y Feng, Eric A Klein
BACKGROUND: Decipher is a validated genomic classifier developed to determine the biological potential for metastasis after radical prostatectomy (RP). OBJECTIVE: To evaluate the ability of biopsy Decipher to predict metastasis and Prostate cancer-specific mortality (PCSM) in primarily intermediate- to high-risk patients treated with RP or radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Two hundred and thirty-five patients treated with either RP (n=105) or RT±androgen deprivation therapy (n=130) with available genomic expression profiles generated from diagnostic biopsy specimens from seven tertiary referral centers...
May 18, 2017: European Urology
https://www.readbyqxmd.com/read/28400167/validation-of-a-genomic-risk-classifier-to-predict-prostate-cancer-specific-mortality-in-men-with-adverse-pathologic-features
#2
R Jeffrey Karnes, Voleak Choeurng, Ashley E Ross, Edward M Schaeffer, Eric A Klein, Stephen J Freedland, Nicholas Erho, Kasra Yousefi, Mandeep Takhar, Elai Davicioni, Matthew R Cooperberg, Bruce J Trock
BACKGROUND: Risk of prostate cancer-specific mortality (PCSM) is highly variable for men with adverse pathologic features at radical prostatectomy (RP); a majority will die of other causes. Accurately stratifying PCSM risk can improve therapy decisions. OBJECTIVE: Validate the 22 gene Decipher genomic classifier (GC) to predict PCSM in men with adverse pathologic features after RP. DESIGN, SETTING, AND PARTICIPANTS: Men with adverse pathologic features: pT3, pN1, positive margins, or Gleason score >7 who underwent RP in 1987-2010 at Johns Hopkins, Cleveland Clinic, Mayo Clinic, and Durham Veteran's Affairs Hospital...
April 8, 2017: European Urology
https://www.readbyqxmd.com/read/28376608/decision-making-tools-in-prostate-cancer-from-risk-grouping-to-nomograms
#3
Paolo Fontanella, Luigi Benecchi, Angelica Grasso, Vipul Patel, David Albala, Claude Abbou, Francesco Porpiglia, Marco Sandri, Bernardo Rocco, Giampaolo Bianchi
INTRODUCTION: Prostate cancer (PCa) is the most common solid neoplasm and the second leading cause of cancer death in men. After the Partin tables were developed, a number of predictive and prognostic tools became available for risk stratification. These tools have allowed the urologist to better characterize this disease and lead to more confident treatment decisions for patients. The purpose of this study is to critically review the decision-making tools currently available to the Urologist, from the moment when PCa is first diagnosed until patients experience metastatic progression and death...
March 30, 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/28358655/individual-patient-level-meta-analysis-of-the-performance-of-the-decipher-genomic-classifier-in-high-risk-men-after-prostatectomy-to-predict-development-of-metastatic-disease
#4
Daniel E Spratt, Kasra Yousefi, Samineh Deheshi, Ashley E Ross, Robert B Den, Edward M Schaeffer, Bruce J Trock, Jingbin Zhang, Andrew G Glass, Adam P Dicker, Firas Abdollah, Shuang G Zhao, Lucia L C Lam, Marguerite du Plessis, Voleak Choeurng, Zaid Haddad, Christine Buerki, Elai Davicioni, Sheila Weinmann, Stephen J Freedland, Eric A Klein, R Jeffrey Karnes, Felix Y Feng
Purpose To perform the first meta-analysis of the performance of the genomic classifier test, Decipher, in men with prostate cancer postprostatectomy. Methods MEDLINE, EMBASE, and the Decipher genomic resource information database were searched for published reports between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher test. Multivariable Cox proportional hazards models fit to individual patient data were performed; meta-analyses were conducted by pooling the study-specific hazard ratios (HRs) using random-effects modeling...
March 30, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28330676/stromal-gene-expression-is-predictive-for-metastatic-primary-prostate-cancer
#5
Fan Mo, Dong Lin, Mandeep Takhar, Varune Rohan Ramnarine, Xin Dong, Robert H Bell, Stanislav V Volik, Kendric Wang, Hui Xue, Yuwei Wang, Anne Haegert, Shawn Anderson, Sonal Brahmbhatt, Nicholas Erho, Xinya Wang, Peter W Gout, James Morris, R Jeffrey Karnes, Robert B Den, Eric A Klein, Edward M Schaeffer, Ashley Ross, Shancheng Ren, S Cenk Sahinalp, Yingrui Li, Xun Xu, Jun Wang, Jian Wang, Martin E Gleave, Elai Davicioni, Yinghao Sun, Yuzhuo Wang, Colin C Collins
BACKGROUND: Clinical grading systems using clinical features alongside nomograms lack precision in guiding treatment decisions in prostate cancer (PCa). There is a critical need for identification of biomarkers that can more accurately stratify patients with primary PCa. OBJECTIVE: To identify a robust prognostic signature to better distinguish indolent from aggressive prostate cancer (PCa). DESIGN, SETTING, AND PARTICIPANTS: To develop the signature, whole-genome and whole-transcriptome sequencing was conducted on five PCa patient-derived xenograft (PDX) models collected from independent foci of a single primary tumor and exhibiting variable metastatic phenotypes...
March 19, 2017: European Urology
https://www.readbyqxmd.com/read/28202223/filtration-based-enrichment-of-circulating-tumor-cells-from-all-prostate-cancer-risk-groups
#6
Julius Adebayo Awe, Jeff Saranchuk, Darrel Drachenberg, Sabine Mai
OBJECTIVE: To combine circulating tumor cell (CTC) isolation by filtration and immunohistochemistry to investigate the presence of CTCs in low, intermediate, and high-risk prostate cancer (PCa). CTCs isolated from these risk groups stained positive for both cytokeratin and androgen receptors, but negative for CD45. PATIENTS AND METHODS: Blood samples from 41 biopsy confirmed patients with PCa at different clinical stages such as low, intermediate, and high risk were analyzed...
February 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28148485/prostate-cancer-recurrence-genomic-clues
#7
(no author information available yet)
In the largest genomic analysis of intermediate-risk prostate cancer samples to date, researchers have uncovered a five-element molecular signature that could help pinpoint patients whose disease is likely to recur and metastasize even after surgery or radiotherapy. They hope to develop a prognostic assay from this signature that can be used in the clinic.
February 1, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28117383/utilization-of-biopsy-based-genomic-classifier-to-predict-distant-metastasis-after-definitive-radiation-and-short-course-adt-for-intermediate-and-high-risk-prostate-cancer
#8
P L Nguyen, N E Martin, V Choeurng, B Palmer-Aronsten, T Kolisnik, C J Beard, P F Orio, M D Nezolosky, Y-W Chen, H Shin, E Davicioni, F Y Feng
BACKGROUND: We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT). METHODS: We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive radiation plus a median of 6 months of ADT (range 3-39 months) from 2001-2013 at a single center and had available biopsy tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement were macrodissected for RNA extraction...
June 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28024937/curative-brachytherapy-for-prostate-cancer-in-african-caribbean-patients-a-retrospective-analysis-of-370-consecutive-cases
#9
V Atallah, N Leduc, M Creoff, P Sargos, T Taouil, P Escarmant, V Vinh-Hung
PURPOSE: Prostate cancer is the most frequent malignancy in African-Caribbean men, a population sharing common genetic traits with African-American (AA) but presenting also genomic and epidemiologic specificities. Despite socioeconomic disparities with French mainland, all patients were treated within the French state-financed equal-access health care system. In this study, we report biochemical outcomes of patients treated by brachytherapy in our department from 2005 to 2014 in an African-Caribbean population...
December 23, 2016: Brachytherapy
https://www.readbyqxmd.com/read/27987030/improved-decision-making-in-intermediate-risk-prostate-cancer-a-multicenter-study-on-pathologic-and-oncologic-outcomes-after-radical-prostatectomy
#10
Jean Baptiste Beauval, Guillaume Ploussard, Bastien Cabarrou, Mathieu Roumiguié, Adil Ouzzane, Jérome Gas, Annabelle Goujon, Gautier Marcq, Romain Mathieu, Sébastien Vincendeau, Xavier Cathelineau, Pierre Mongiat-Artus, Laurent Salomon, Michel Soulié, Arnaud Méjean, Alexandre de La Taille, Morgan Rouprêt, François Rozet
BACKGROUND: Prognoses for intermediate-risk prostate cancer (PCa) remain heterogeneous. Improved substratification could optimize treatment and monitoring strategies. The objective was to validate this subclassification in a radical prostatectomy (RP) series. METHODS: Between 2000 and 2011, 4038 patients who underwent RP for intermediate-risk PCa in seven French academic centers were included. Unfavorable intermediate-risk (UIR) PCa was defined as having a primary Gleason score of 4, ≥50% positive biopsy cores (PPBC), or more than one D'Amico intermediate-risk factor (i...
December 16, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27746147/what-is-the-best-way-not-to-treat-prostate-cancer
#11
REVIEW
Michael S Leapman, Peter R Carroll
INTRODUCTION: Selective treatment approaches for prostate cancer (PCa) are warranted given the highly varied nature of the disease and the consequences associated with definitive therapy. MATERIALS AND METHODS: We present a stepwise overview of strategies optimized to not treat PCa, ranging from improved screening practices that seek to maximize the yield at initial diagnosis, as well as refinements to clinical risk prediction and the performance of active surveillance...
October 13, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27725639/oligometastatic-prostate-cancer-definitions-clinical-outcomes-and-treatment-considerations
#12
REVIEW
Jeffrey J Tosoian, Michael A Gorin, Ashley E Ross, Kenneth J Pienta, Phuoc T Tran, Edward M Schaeffer
The oligometastatic state has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastases. With improvements in diagnostic modalities such as functional imaging, oligometastatic prostate cancer is being diagnosed with greater frequency than ever before. Furthermore, the paradigm for treatment of advanced prostate cancers is shifting toward a more aggressive approach. Many questions surround the understanding of the process and consequences of oligometastasis, meaning that the contemporary literature offers a wide variety of definitions of oligometastatic prostate cancer...
January 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27708722/pitx3-promoter-methylation-is-a-prognostic-biomarker-for-biochemical-recurrence-free-survival-in-prostate-cancer-patients-after-radical-prostatectomy
#13
Emily Eva Holmes, Diane Goltz, Verena Sailer, Maria Jung, Sebastian Meller, Barbara Uhl, Jörn Dietrich, Magda Röhler, Jörg Ellinger, Glen Kristiansen, Dimo Dietrich
BACKGROUND: Molecular biomarkers that might help to distinguish between more aggressive and clinically insignificant prostate cancers (PCa) are still urgently needed. Aberrant DNA methylation as a common molecular alteration in PCa seems to be a promising source for such biomarkers. In this study, PITX3 DNA methylation (mPITX3) and its potential role as a prognostic biomarker were investigated. Furthermore, mPITX3 was analyzed in combination with the established PCa methylation biomarker PITX2 (mPITX2)...
2016: Clinical Epigenetics
https://www.readbyqxmd.com/read/27675556/the-use-of-a-biopsy-based-genomic-classifier-to-predict-the-risk-of-distant-metastasis-after-definitive-radiation-and-short-course-androgen-deprivation-therapy-for-intermediate-and-high-risk-prostate-cancer
#14
P L Nguyen, N E Martin, B J Palmer-Aronsten, V Choeurng, T Kolisnik, C J Beard, M D Nezolosky, Y W Chen, H Shin, E Davicioni, F Feng
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27651837/epigenetic-signature-of-gleason-score-and-prostate-cancer-recurrence-after-radical-prostatectomy
#15
Milan S Geybels, Jonathan L Wright, Marina Bibikova, Brandy Klotzle, Jian-Bing Fan, Shanshan Zhao, Ziding Feng, Elaine A Ostrander, Daniel W Lin, Peter S Nelson, Janet L Stanford
BACKGROUND: Identifying the subset of patients with clinically localized prostate cancer (PCa) at the highest risk of recurrence remains challenging, and better prognostic markers are needed. Gleason score is the best predictor of PCa aggressiveness and prognosis. In the present study, we generated an epigenetic signature based on high versus low Gleason score tumors and evaluated its ability to predict recurrence after radical prostatectomy. METHODS: Genome-wide DNA methylation data from The Cancer Genome Atlas (TCGA; no...
2016: Clinical Epigenetics
https://www.readbyqxmd.com/read/27574020/decipher-correlation-patterns-post-prostatectomy-initial-experience-from-2%C3%A2-342-prospective-patients
#16
R B Den, M Santiago-Jimenez, J Alter, M Schliekelman, J R Wagner, J F Renzulli Ii, D I Lee, C G Brito, K Monahan, B Gburek, N Kella, G Vallabhan, F Abdollah, E J Trabulsi, C D Lallas, L G Gomella, T L Woodlief, Z Haddad, L L C Lam, S Deheshi, Q Wang, V Choeurng, M du Plessis, J Jordan, B Parks, H Shin, C Buerki, K Yousefi, E Davicioni, V R Patel, N L Shah
BACKGROUND: Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we examined the correlation patterns of Decipher assay to understand the relationship between the Decipher and patient tumor characteristics. METHODS: De-identified Decipher test results (including Decipher risk scores and clinicopathologic data) from 2 342 consecutive radical prostatectomy (RP) patients tested between January and September 2015 were analyzed...
December 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27451135/intratumoral-and-intertumoral-genomic-heterogeneity-of-multifocal-localized-prostate-cancer-impacts-molecular-classifications-and-genomic-prognosticators
#17
Lei Wei, Jianmin Wang, Erika Lampert, Simon Schlanger, Adam D DePriest, Qiang Hu, Eduardo Cortes Gomez, Mitsuko Murakam, Sean T Glenn, Jeffrey Conroy, Carl Morrison, Gissou Azabdaftari, James L Mohler, Song Liu, Hannelore V Heemers
BACKGROUND: Next-generation sequencing is revealing genomic heterogeneity in localized prostate cancer (CaP). Incomplete sampling of CaP multiclonality has limited the implications for molecular subtyping, stratification, and systemic treatment. OBJECTIVE: To determine the impact of genomic and transcriptomic diversity within and among intraprostatic CaP foci on CaP molecular taxonomy, predictors of progression, and actionable therapeutic targets. DESIGN, SETTING, AND PARTICIPANTS: Four consecutive patients with clinically localized National Comprehensive Cancer Network intermediate- or high-risk CaP who did not receive neoadjuvant therapy underwent radical prostatectomy at Roswell Park Cancer Institute in June-July 2014...
February 2017: European Urology
https://www.readbyqxmd.com/read/27136742/efficacy-of-post-operative-radiation-in-a-prostatectomy-cohort-adjusted-for-clinical-and-genomic-risk
#18
A E Ross, R B Den, K Yousefi, B J Trock, J Tosoian, E Davicioni, D J S Thompson, V Choeurng, Z Haddad, P T Tran, E J Trabulsi, L G Gomella, C D Lallas, F Abdollah, F Y Feng, E A Klein, A P Dicker, S J Freedland, R J Karnes, E M Schaeffer
BACKGROUND: To date, there have been no published trials examining the impact of salvage radiation therapy (SRT) in the post-operative setting for prostate cancer (PCa). We conducted a retrospective, comparative study of post-operative radiation following radical prostatectomy (RP) for men with pT3 disease or positive margins (adverse pathological features, APF). METHODS: 422 PCa men treated at four institutions with RP and having APF were analyzed with a primary end point of metastasis...
September 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27044421/incorporation-of-tissue-based-genomic-biomarkers-into-localized-prostate-cancer-clinics
#19
REVIEW
Marco Moschini, Martin Spahn, Agostino Mattei, John Cheville, R Jeffrey Karnes
Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®...
April 4, 2016: BMC Medicine
https://www.readbyqxmd.com/read/26806658/utilization-of-a-genomic-classifier-for-prediction-of-metastasis-following-salvage-radiation-therapy-after-radical-prostatectomy
#20
Stephen J Freedland, Voleak Choeurng, Lauren Howard, Amanda De Hoedt, Marguerite du Plessis, Kasra Yousefi, Lucia L Lam, Christine Buerki, Seong Ra, Bruce Robbins, Edouard J Trabulsi, Nikhil L Shah, Firas Abdollah, Felix Y Feng, Elai Davicioni, Adam P Dicker, Robert J Karnes, Robert B Den
BACKGROUND: Despite salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) after radical prostatectomy (RP), some patients still progress to metastases. Identifying these men would allow them to undergo systemic therapy including testing novel therapies to reduce metastases risk. OBJECTIVE: To test whether the genomic classifier (GC) predicts development of metastatic disease. DESIGN, SETTING, AND PARTICIPANTS: Retrospective multi-center and multi-ethnic cohort study from two academic centers and one Veterans Affairs Medical Center in the United States involving 170 men receiving SRT for recurrent PCa post-RP...
October 2016: European Urology
keyword
keyword
96307
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"